Rational Design of Live Biotherapeutic Products for the Prevention of Clostridioides difficile Infection.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 39316685.
- Also identified by DOI 10.1093/infdis/jiae470 and PMC identifier 12247820.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Clostridioides difficile infection (CDI) is a major cause of healthcare- and antibiotic-associated diarrhea. While fecal microbiota transplantation (FMT) shows promise for recurrent CDI, its mechanisms and long-term safety are not fully understood. Live biotherapeutic products (LBPs) using predefined bacterial consortia offer an alternative option, but the rational design of LBPs remains challenging. Here, we employ a computational pipeline and three metagenomic datasets to identify microbial strains for LBPs targeting CDI. We constructed the CDI-related microbial genome catalog, comprising 3741 nonredundant metagenome-assembled genomes (nrMAGs), and identified multiple potential protective nrMAGs, including strains from Dorea formicigenerans, Oscillibacter welbionis, and Faecalibacterium prausnitzii. Importantly, some of these protective nrMAGs were found to play an important role in FMT success, and most top protective nrMAGs can be validated by various previous findings. Our results demonstrate a framework for selecting microbial strains targeting CDI, paving the way for the computational design of LBPs against other enteric infections.
Medical subject headings
- Clostridium Infections
- Clostridioides difficile
- Fecal Microbiota Transplantation
- Biological Products
- Biological Therapy